Literature DB >> 22689685

Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma.

Monika Schmelz, Santiago Montes-Moreno, Miguel Piris, Sarah T Wilkinson, Lisa M Rimsza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22689685      PMCID： PMC3487566          DOI： 10.3324/haematol.2011.060186

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

Authors:  Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

2.  Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.

Authors:  I Simonitsch-Klupp; I Hauser; G Ott; J Drach; J Ackermann; J Kaufmann; A Weltermann; H T Greinix; C Skrabs; C Dittrich; D Lutz; R Pötter; C Mannhalter; K Lechner; A Chott; U Jaeger
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

3.  Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

Authors:  Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael Leblanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

4.  Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.

Authors:  Santiago Montes-Moreno; Ana-Rosa Gonzalez-Medina; Socorro-María Rodriguez-Pinilla; Lorena Maestre; Lydia Sanchez-Verde; Giovanna Roncador; Manuela Mollejo; Juan F García; Javier Menarguez; Carlos Montalbán; M Carmen Ruiz-Marcellan; Eulogio Conde; Miguel A Piris
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

5.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

Authors:  Lisa M Rimsza; Robin A Roberts; Thomas P Miller; Joseph M Unger; Michael LeBlanc; Rita M Braziel; Dennis D Weisenberger; Wing C Chan; H Konrad Muller-Hermelink; Elaine S Jaffe; Randy D Gascoyne; Elias Campo; Deborah A Fuchs; Catherine M Spier; Richard I Fisher; Jan Delabie; Andreas Rosenwald; Louis M Staudt; Thomas M Grogan
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

6.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

Review 7.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087
  7 in total
  6 in total

1.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.

Authors:  Soham D Puvvada; Hongli Li; Lisa M Rimsza; Steven H Bernstein; Richard I Fisher; Michael LeBlanc; Monika Schmelz; Betty Glinsmann-Gibson; Thomas P Miller; Anne-Marie Maddox; Jonathan W Friedberg; Sonali M Smith; Daniel O Persky
Journal:  Leuk Lymphoma       Date:  2016-01-12

2.  Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.

Authors:  Samantha Kendrick; Lisa M Rimsza; David W Scott; Graham W Slack; Pedro Farinha; King L Tan; Daniel Persky; Soham Puvvada; Joseph M Connors; Laurie Sehn; Randy D Gascoyne; Monika Schmelz
Journal:  Virchows Arch       Date:  2016-11-25       Impact factor: 4.064

Review 3.  Biological and clinical significance of epigenetic alterations in B-cell lymphomas.

Authors:  Daisuke Ennishi
Journal:  Int J Hematol       Date:  2022-10-08       Impact factor: 2.319

Review 4.  Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review.

Authors:  Lynette Luria; Johnny Nguyen; Jun Zhou; Michael Jaglal; Lubomir Sokol; Jane L Messina; Domenico Coppola; Ling Zhang
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

5.  Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.

Authors:  Julia Garcia-Reyero; Nerea Martinez Magunacelaya; Sonia Gonzalez de Villambrosia; Sanam Loghavi; Angela Gomez Mediavilla; Raul Tonda; Sergi Beltran; Marta Gut; Ainara Pereña Gonzalez; Emanuele d'Ámore; Carlo Visco; Joseph D Khoury; Santiago Montes-Moreno
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

Review 6.  Plasmablastic lymphoma: An update.

Authors:  Jenique Bailly; Nicholas Jenkins; Dharshnee Chetty; Zainab Mohamed; Estelle R Verburgh; Jessica J Opie
Journal:  Int J Lab Hematol       Date:  2022-09       Impact factor: 3.450
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.